Affibody
Affibody is recorded as a service provider in 1 clinical trial. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 1 of 1 trials · Latest update first
A multicentre, prospective, open-label study with [68Ga]Ga-ABY-025 PET-imaging to characterize HER2-expression and explore the therapy-predictive value for HER2-antibody drug conjugates in patients with metastatic breast cancer.
Sponsor Karolinska University Hospital
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Affibody?
The 2026-10-09 snapshot links Affibody to 1 distinct CTIS trials. Recorded services include Creator of the precursor ABY-025. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Affibody?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Recorded phases include Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Affibody conducted?
The linked trials record locations in 1 country, including Sweden. These are trial locations, not confirmed office locations or countries where Affibody delivered services.
What can this page tell me about Affibody's trial experience?
Browse 1 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Affibody. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Affibody AB